Followers | 144 |
Posts | 27707 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Tuesday, March 04, 2014 5:35:03 AM
Tuesday 4 March 2014
PETACH TIKVA, Israel, March 3, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (TASE:CFBI), (NYSE MKT:CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the addition of a key opinion leader, medical and industry expert, Dr. Lee S. Simon, as consultant to assist in the regulatory and clinical development of the company's CF101 rheumatoid arthritis program.
The need to bring Dr. Simon on board arose after the company successfully concluded a Phase II study in Rheumatoid Arthritis where CF101, the lead drug candidate, showed safety and efficacy when given orally to patients as a stand alone drug. Can-Fite is doing all the preparatory work for an end of Phase II meeting with the FDA to present a registration plan, a move that is designed to also support a partnership with a pharmaceutical company.
Dr. Simon is a rheumatologist and well-known consultant that provides insightful design and FDA regulatory guidance for new drug development programs. Throughout his extensive career as a clinical rheumatologist, academic, and consulting expert, Dr. Simon has authored more than 110 articles, chapters, and publications and held various leading roles in the field which also include appointment as Division Director of Analgesic, Anti-inflammatory and Ophthalmologic Drug Products, a review division within the Center for Drug Evaluation and Research of the FDA.
Dr. Pnina Fishman, Chief Executive Officer of Can-Fite, commented, "As we focus on the next phase of our rheumatoid arthritis development plans for our proprietary drug CF101, we are extremely pleased to draw on the expertise of such a well-regarded leader in the field. Dr. Simon has successfully worked on developing new treatments in the rheumatology field and we are fortunate to be able to leverage that knowledge as we progress with our studies. In addition, Dr. Simon will also be able to guide us from an FDA regulatory perspective which we hope will help expedite our time to market."
Recent MIGI News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 09:48:55 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for August 2024 • GlobeNewswire Inc. • 09/16/2024 10:01:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 10:00:16 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2024 10:09:01 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 10:10:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 09:05:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/09/2024 09:05:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 01:26:21 PM
- Mawson Infrastructure Group Expands to Ohio for AI/HPC Expansion • GlobeNewswire Inc. • 08/27/2024 12:50:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/27/2024 12:48:56 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for July 2024 • GlobeNewswire Inc. • 08/22/2024 12:50:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/22/2024 12:48:25 PM
- Mawson Infrastructure Group Inc. Reports Q2 2024 Financial Results • GlobeNewswire Inc. • 08/19/2024 09:15:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 09:15:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2024 08:57:21 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 08:30:02 PM
- Mawson Infrastructure Group Inc. to Join World Summit AI (Artificial Intelligence) in October 2024 • GlobeNewswire Inc. • 08/14/2024 12:30:18 PM
- Mawson Infrastructure Group Inc. Expands into AI and HPC Markets and Announces the Signing of AI/HPC Colocation Agreement for 20 MW • GlobeNewswire Inc. • 08/12/2024 12:45:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 12:45:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 09:00:35 PM
- Mawson Infrastructure Group Inc. to Present at the 2024 Gateway Conference in San Francisco, CA • GlobeNewswire Inc. • 08/06/2024 12:45:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 09:02:41 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for June 2024 • GlobeNewswire Inc. • 07/18/2024 08:53:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 08:46:03 PM
- Mawson Infrastructure Group Announces Several Recent New Hires to Further Drive Transformation and Growth Initiatives • GlobeNewswire Inc. • 07/17/2024 08:45:17 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM